Red Light for Knee Osteoarthritis: Wavelengths, Pain & Function

Does red light therapy help knee osteoarthritis?

Knee osteoarthritis is one of the more credible musculoskeletal uses of photobiomodulation. A 2024 placebo-controlled systematic review found a statistically significant reduction in pain at rest and possible disability benefits, but rated the evidence very low certainty and did not support PBM as a stand-alone replacement for established osteoarthritis care.

A broader 2025 umbrella review found moderate-certainty evidence for improvement in osteoarthritis-related disability across the PBM evidence base. That makes PBM a reasonable adjunct to discuss—not a cure and not a substitute for exercise therapy, weight management where relevant, analgesic strategies or clinical assessment.

Which wavelengths are studied for knee osteoarthritis?

Knee studies use both red and near-infrared light, with near-infrared wavelengths particularly common because the target tissues sit beneath skin and subcutaneous tissue. A 2024 network meta-analysis specifically compared wavelength groups, reinforcing that wavelength may influence outcomes.

The practical lesson is not that one nanometer value is universally best. Clinical trials also differ in laser versus LED delivery, treatment points around the knee, total energy, session frequency and whether light is applied directly over the joint line or surrounding tissues.

A panel emitting 660 and 850 nm therefore overlaps with common PBM research bands, but it does not automatically reproduce a knee-osteoarthritis trial.

Joint pain is not one diagnosis

“Knee pain” can reflect osteoarthritis, meniscal injury, ligament injury, inflammatory arthritis, gout, referred pain, tendinopathy or other causes. Evidence from osteoarthritis trials should not be silently transferred to all painful knees.

Red flags such as a hot swollen joint, fever, inability to bear weight, major trauma, locking, sudden severe swelling or a new calf swelling deserve clinical assessment rather than home wavelength experimentation.

What outcomes have actually been measured?

Trials commonly assess:

• pain at rest or during movement;
• WOMAC or similar pain/function scores;
• stiffness;
• timed functional tests;
• walking or gait measures;
• short-term disability.

Those outcomes are different from proving that PBM regrows cartilage or reverses structural osteoarthritis. Pain relief should not be rewritten as cartilage regeneration.

Is 850 nm the best wavelength for joints?

No single wavelength currently deserves that universal label.

Near-infrared wavelengths around the 800-nm range are heavily represented in joint and musculoskeletal PBM, but trial-level response depends on dose and treatment geometry. Wavelength-only rankings can be misleading when one trial uses a point-contact laser and another uses a broad LED field.

Dose matters

A headline panel irradiance is not enough to infer a clinical joint dose. Useful interpretation requires treatment distance, illuminated area, exposure time and whether the intended target resembles the treatment geometry used in research.

Higher irradiance is not automatically better. PBM research commonly assumes a dose-response relationship in which excessive or poorly matched exposure may not improve outcomes.

Where PBM fits in an osteoarthritis plan

The most defensible role is adjunctive symptom management. It may be considered alongside evidence-based exercise, strengthening, mobility work, weight management where indicated, medication and other individualized care.

If a device is being compared for this purpose, prioritize transparent wavelength and irradiance data, reproducible timer controls, appropriate coverage and independent output testing. See Red Light Device Specifications Explained and the Red Light Panel Specifications catalog.

Back to the broader Red Light Therapy by Condition hub.